{"id":390638,"date":"2026-04-21T15:43:13","date_gmt":"2026-04-21T15:43:13","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/390638\/"},"modified":"2026-04-21T15:43:13","modified_gmt":"2026-04-21T15:43:13","slug":"new-cochrane-review-questions-alzheimers-drugs-czech-company-unveils-alternative","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/390638\/","title":{"rendered":"New Cochrane Review Questions Alzheimer\u2019s Drugs; Czech Company Unveils Alternative"},"content":{"rendered":"

\"Elderly<\/a><\/p>\n

A patient undergoes combined molecular hydrogen inhalation and VR cognitive rehabilitation \u2014 a dual-therapy approach developed by H2 Global Group and VR Vitalis for Alzheimer’s and dementia treatment.<\/p>\n

The latest Cochrane review finds \u201ctrivial\u201d clinical benefits in new Alzheimer\u2019s drugs – European innovator proposes a patented solution using molecular hydrogen<\/p>\n

\u201cWith molecular hydrogen, we address the \u2018hardware\u2019 of the brain, Virtual Reality acts as the \u2018software\u2019, stimulating neuroplasticity. It is a powerful synergistic effect.\u201d<\/p>\n

\u2014 explains PharmDr. Milan Kraj\u00ed\u010dek<\/p>\n

PRAGUE, CZECH REPUBLIC, April 21, 2026 \/EINPresswire.com<\/a>\/ — Highly anticipated Alzheimer\u2019s drugs are facing intense scientific scrutiny following a new Cochrane review. The analysis by one of the world\u2019s most respected institutions for evaluating medical evidence suggests that amyloid-targeting biological drugs fail to deliver clinically meaningful benefits, while carrying astronomical costs and increased risk of severe adverse effects. In response, Czech-based H2 Global Group has presented a patented alternative utilizing molecular hydrogen to the governments of all 27 EU member states.<\/p>\n

On April 16, 2026, Cochrane published a systematic review of anti-amyloid monoclonal antibodies in patients with mild cognitive impairment and mild dementia due to Alzheimer\u2019s disease. The analysis aggregated data from 17 clinical trials involving over 20,000 participants. According to the authors, the effect of these drugs is merely \u201ctrivial,\u201d falling short of clinically meaningful benefit. The review also highlights increased incidence of brain swelling and microhemorrhages (ARIA).<\/p>\n

Lead author Francesco Nonino of the IRCCS Institute of Neurological Sciences in Bologna stated that these drugs do not provide a meaningful clinical difference. The authors emphasize that future Alzheimer\u2019s research must pivot toward alternative mechanisms of action.<\/p>\n

Global Media and Experts React<\/p>\n

The Guardian called the effect \u201ctrivial,\u201d The New York Times detailed the fierce debate over clinical value, the BBC noted patients are unlikely to benefit, and Scientific American found the clinical difference \u201cabsent or trivial.\u201d The UK\u2019s Mirror referred to the \u201cbombshell\u201d finding that these medicines do not work.

\nProfessor Robert Howard (University College London) expressed that the effects had been presented too optimistically to patients\u2019 families. Professor Paresh Malhotra (Imperial College London) cautioned that research must look beyond the amyloid pathway.<\/p>\n

Annual treatment costs hover around \u20ac77,000 ($82,000 USD) per patient, a key reason why several European nations face reimbursement hurdles for these drugs.<\/p>\n

The European Response: Molecular Hydrogen and VR<\/p>\n

H2 Global Group dispatched a strategic proposal to all 27 EU leaders on April 17, centering on the combination of molecular hydrogen therapy and VR cognitive rehabilitation developed with a portfolio VR company, whose solution is already a certified medical device (MDR) deployed in over 40 European hospitals.<\/p>\n

PharmDr. Milan Kraj\u00ed\u010dek, Chief Medical Officer at H2 Global Group, notes that an exclusive focus on beta-amyloid is unlikely to solve the disease. The company advances an approach targeting oxidative stress and neuroinflammation alongside neurodegeneration.<\/p>\n

Its strategy is anchored in the patent \u201cProphylactic or Therapeutic Agent for Dementia\u201d (EP 3701956 B1), being expanded globally including the US. It protects the use of gaseous hydrogen in Alzheimer\u2019s-type dementia, including cases where standard treatments have failed, and covers preventative use in early cognitive decline. The scientific foundation was laid by Professor Shigeo Ohta of Nippon Medical School, whose landmark 2007 Nature Medicine study demonstrated hydrogen\u2019s therapeutic antioxidant effects. Subsequent studies confirmed its neuroprotective properties in dementia.<\/p>\n

In January 2026, the firm launched a clinical study approved by S\u00daKL and the Ethics Committee of University Hospital Ostrava, aiming to register a unique medical device utilizing molecular hydrogen.<\/p>\n

\u201cWith molecular hydrogen, we address the \u2018hardware\u2019 of the brain, clearing inflammation and oxidative stress. Virtual reality acts as the \u2018software\u2019, stimulating neuroplasticity. It is a powerful synergistic effect,\u201d explains Dr. Kraj\u00ed\u010dek.<\/p>\n

A Paradigm Shift in Cost and Accessibility<\/p>\n

\u201cThe Czech Republic today has a historic opportunity to stand at the genesis of a systemic solution to the greatest health and social challenge of the 21st century: the aging population and the dementia epidemic. We possess unique Japanese-Czech technology backed by patents and scientific evidence, alongside a top-tier Czech-Japanese team. We have an active, regulator-approved clinical study and a ready platform capable of reaching all 27 EU member states. If we can bridge Czech innovation with pan-European collaboration, the largest clinical study of its kind in history could emerge from the Czech Republic \u2014 a study that offers a safe, accessible, and functional solution for tens of millions of patients and their families. The time for waiting is over; we must act immediately,\u201d concludes David Mar\u0161\u00e1lek, CEO and Founder of H2 Global Group.<\/p>\n

Sources: Cochrane Library; BMJ; Science Media Centre; The New York Times; The Guardian; BBC News; Scientific American; US News\/HealthDay; The Mirror; Ohsawa et al., Nature Medicine 13, 688\u2013694 (2007); Noda et al., Current Pharmaceutical Design 26(30), 3680\u20133693 (2021); Ohta et al., Current Alzheimer Research 15(5), 482\u2013492 (2018). Full references at www.H2times.news<\/a>.<\/p>\n

David Marsalek
H2 Global Group
777 724 726
david.marsalek@H2global.group<\/p>\n

\n Legal Disclaimer:\n<\/p>\n

\n EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
\n for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
\n article. If you have any complaints or copyright issues related to this article, kindly contact the author above.\n<\/p>\n

\"\"<\/p>\n

You just read:<\/p>\n

News Provided By<\/p>\n

\n April 21, 2026, 14:47 GMT\n <\/p>\n

Distribution channels:
\n Banking, Finance & Investment Industry<\/a>, Beauty & Hair Care<\/a>, Business & Economy<\/a>, Chemical Industry<\/a>, Culture, Society & Lifestyle<\/a>, Emergency Services<\/a>, Healthcare & Pharmaceuticals Industry<\/a>, Insurance Industry<\/a>, International Organizations<\/a>, U.S. Politics<\/a> …<\/p>\n

\n
EIN Presswire’s priority is author transparency. We do our best to weed out false and misleading content. The content above is
\nthe sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.\n <\/p>\n","protected":false},"excerpt":{"rendered":"A patient undergoes combined molecular hydrogen inhalation and VR cognitive rehabilitation \u2014 a dual-therapy approach developed by H2…\n","protected":false},"author":2,"featured_media":390639,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[202095,202096,134,111,139,69],"class_list":{"0":"post-390638","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-h2-global-group-h2-times","9":"tag-h2-medical-technologies-vr-vitalis","10":"tag-health","11":"tag-new-zealand","12":"tag-newzealand","13":"tag-nz"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/390638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=390638"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/390638\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/390639"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=390638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=390638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=390638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}